CoChat
Sign Up
Cited by 131Attention Deficit Hyperactivity DisorderSchizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD

Rösler, Michael, Retz, Wolfgang, Fischer, Roland, Ose, Claudia, Alm, Barbara, Deckert, Jürgen, Philipsen, Alexandra, Herpertz, Sabine +1 more·2010·The World Journal of Biological Psychiatry
DOI 10.3109/15622971003624197
Open this paper in CoChat — free account

Abstract

OBJECTIVES: Treatment investigations with methylphenidate in adults with ADHD focus preferentially on the classical psychopathology: inattention, hyperactivity and impulsivity. ADHD-associated emotional symptoms, which are frequently present at least in ADHD subpopulations, were studied rarely. The vast majority of the placebo-controlled trials had observation periods between 4 and 8 weeks. To assess the medium- to long-term effects of extended release methylphenidate (MPH-ER) on emotional symptoms and other psychopathology frequently seen in ADHD patients, we conducted a large-scale, multicenter treatment study. METHODS: We performed a randomised, 24-week, double-blind, placebo-controlled study in adults with ADHD. The diagnosis was made on the basis of the DSM-IV criteria, which were confirmed by clinical history and a structured psychopathological interview and the use of rating instruments. 363 patients were randomized to MPH-ER or placebo at a ratio of 2:1. The duration of the titration period was 5 weeks followed by a maintainance phase of 19 weeks. The efficacy measures were the observer rated 10-item Emotional Dysregulation Scale (EDS) derived from the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) and a self-report, six-item Emotional Lability Scale (ELS) extracted from the long version of the Conners Adult ADHD Self Report Scale (CAARS:S:L). In addition we used the SCL-90-R for the assessment of ADHD associated and comorbid psychopathology. RESULTS: MPH-ER was statistically superior to placebo in reducing emotional symptoms as assessed by the EDS and the ELS. Obsessive-compulsive symptoms and those of problems with self-concept declined until the end of the observation period. The decline was more pronounced in MPH-ER treated individuals. The effects remained robust during the entire maintenance period until week 24. Symptoms of anxiety, depression, anger and hostility, phobia, paranoid ideations and psychoticism were not improved. CONCLUSIONS: MPH-ER appears to be an efficacious treatment for emotional symptoms with ADHD. Also obsessive-compulsive symptoms and problems with self-concept were affected positively.

Integrity signals

Registry

Crossref · 10.3109/15622971003624197

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Psychiatric and behavioral comorbidities often co-occur with ADHD and result in increased difficulties for appropriate diagnoses and treatments.

    “Psychiatric and behavioral comorbidities, such as depression, anxiety disorder, bipolar disorder, substance use, and personality disorders, often co-occur with ADHD and result in increased difficulties for appropriate diagnoses and treatments (Barkley and Brown, 2008; Rosler et al., 2010; Mao and Findling, 2014; Katzman et al., 2017).”

    From A Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD) (2019) · cites this paper as Rosler et al., 2010

  • The effect size for extended-release methylphenidate on emotional lability ranged from 0.28 to 0.4.

    “The effect size ranged from 0.28 to 0.4, which is lower than stimulants’ effect size on diagnostic ADHD symptoms (meta-analyses suggest a range of 0.6–0.8 [36, 37]), but it is still clinically significant.”

    From Using Stimulants to Treat ADHD-Related Emotional Lability (2014) · cites this paper as [34]

  • In a multi-center trial of 363 adults with ADHD, 24 weeks of extended-release methylphenidate produced a significant reduction in emotional lability as assessed by the emotional dysregulation items on the Wender-Reimherr Adult ADHD Scale.

    “Following 24 weeks of treatment with extended release methylphenidate (MPH-ER), there was a significant reduction in emotional lability, as assessed by the emotional dysregulation items on the Wender-Reimherr Adult ADHD Scale [35].”

    From Using Stimulants to Treat ADHD-Related Emotional Lability (2014) · cites this paper as [34]

Cites

Flagged first, then by citations

1 of the 43 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Rösler, M., Retz, W., Fischer, R., Ose, C., Alm, B., Deckert, J., Philipsen, A., Herpertz, S., & Ammer, R.
Affiliations
  • Universitätsklinikum des Saarlandes (DE)
  • Medice (Germany) (DE)
  • Institut für Medizinische Informatik, Biometrie und Epidemiologie (DE)
  • Central Institute of Mental Health (DE)
  • University of Würzburg (DE)
  • University of Freiburg (DE)
  • University of Rostock (DE)
Corresponding author
Rösler, Michael
ORCID
Venue
The World Journal of Biological Psychiatry
Publisher
Informa UK Limited
Published
2010-03-30
Volume
11
Issue
5
Pages
709-718
ISSN
  • 1562-2975 (ISSN-L)
  • 1814-1412
DOI
10.3109/15622971003624197
OpenAlex
W1985528539
Cited by
131
References
43
Citations by year
2026: 3 · 2025: 4 · 2024: 1 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 8 · 2019: 7 · 2018: 6 · 2017: 11 · 2016: 13 · 2015: 11 · 2014: 20 · 2013: 7 · 2012: 9
FWCI
5.67
Type
journal article
Language
en
Open access
closed
Locations
  • The World Journal of Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
adult ADHD, extended-release methylphenidate, emotional symptoms, emotional dysregulation, emotional lability, obsessive-compulsive symptoms, self-concept, long-term treatment efficacy, comorbid psychopathology
MeSH terms
Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Delayed-Action Preparations, Double-Blind Method, Emotions, Female, Follow-Up Studies, Humans, Long-Term Care, Male, Methylphenidate, Middle Aged, Obsessive-Compulsive Disorder, Personality Assessment, Psychometrics, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review